When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Veracyte now meets that criteria, with a jump from 78 to 81 Thursday.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Veracyte is not currently near a potential buy zone. See if the stock goes on to build a sound pattern that could launch a new move.
The company showed 71% EPS growth in the latest quarterly report, while sales growth came in at 21%.
The company earns the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
